TP53 and ovarian serous carcinoma: The study conducted by Ghezalayagh et al. [33] was quite similar to our current research; however, it included both serous and non-serous ovarian carcinomas and aimed to examine the impact of p53 mutations on overall survival rather than on the PFI, i.e., progression-free survival, which is a focus of our study.